Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs021250011) titled 'Anti-aging effects of PAI-1 inhibitor' on Aug. 1.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, basic science
Primary Sponsor: Harigae Hideo
Condition:
N/A
Intervention:
TM5614 is started as 2 tablets (120 mg) once daily (4 weeks) and increased to 3 tablets (180 mg) once daily (12 weeks) if blood and biochemical tests after 1 month show no safety issues
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 01/08/2025
Target Sample Size: 20
To know more, visit https://jrct.mhlw.go.jp/latest-detail/jRCTs02...